Arcturus Therapeutics Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
Portfolio Pulse from Benzinga Newsdesk
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has announced the results of a phase 1/2 study showing that a booster dose of a novel, self-amplifying messenger RNA (sa-mRNA) vaccine against COVID-19 induces a robust, broadly cross-reactive, and durable immune response in adults that remains elevated through 12 months after vaccination. The study used three sa-mRNA vaccines and was presented at the European Scientific Working Group on Influenza's 9th ESWI Influenza Conference in Valencia, Spain. Arcturus collaborated with CSL Seqirus, CSL's vaccine business, for the development of these vaccines.
September 19, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcturus Therapeutics' sa-mRNA COVID-19 vaccine has shown promising results in a phase 1/2 study, potentially leading to increased investor interest and a positive impact on the company's stock.
The positive results from the phase 1/2 study of Arcturus Therapeutics' sa-mRNA COVID-19 vaccine could lead to increased investor interest in the company. This, in turn, could have a positive impact on the company's stock in the short term. The company's collaboration with CSL Seqirus for the development of these vaccines also adds to the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100